» Articles » PMID: 10793061

Vascular Endothelial Growth Factor Receptor-3 in Lymphangiogenesis in Wound Healing

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2000 May 4
PMID 10793061
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular endothelial growth factor receptor-3 (VEGFR-3) is essential for embryonic cardiovascular development, but thereafter becomes confined to the lymphatic endothelium in adult tissues. We have here studied VEGFR-3 expression in experimental wounds of pigs and chronic inflammatory wounds of humans. In healing incisional and punch biopsy wounds made in the dorsal skin of pigs, angiogenic blood vessels, identified by use of the blood vascular endothelial markers vWF and PAL-E and the basal lamina protein laminin, developed into the granulation tissue stroma from day 4 onward, being most abundant on days 5 and 6 and regressing thereafter. VEGFR-3-positive vessels were observed in the granulation tissue from day 5 onward. These vessels were distinct from the PAL-E/laminin/vWF-positive vessels and fewer in number, and they appeared to sprout from pre-existing VEGFR-3-positive lymphatic vessels at the wound edge. Unlike the blood vessels, very few VEGFR-3-positive lymphatic vessels persisted on day 9 and none on day 14. In chronic wounds such as ulcers and decubitus wounds of the lower extremity of humans, VEGFR-3 was also weakly expressed in the vascular endothelium. Our results suggest that transient lymphangiogenesis occurs in parallel with angiogenesis in healing wounds and that VEGFR-3 becomes up-regulated in blood vessel endothelium in chronic inflammatory wounds.

Citing Articles

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.


Hypoxia Preconditioned Serum Hydrogel (HPS-H) Accelerates Dermal Regeneration in a Porcine Wound Model.

Jiang J, Man T, Kirsch M, Knoedler S, Andersen K, Reiser J Gels. 2024; 10(11).

PMID: 39590104 PMC: 11593443. DOI: 10.3390/gels10110748.


Lymphangiogenesis: novel strategies to promote cutaneous wound healing.

Jian Y, Li Y, Zhang Y, Tang M, Deng M, Liu C Burns Trauma. 2024; 12:tkae040.

PMID: 39328366 PMC: 11427083. DOI: 10.1093/burnst/tkae040.


Lymphatic endothelial cell-targeting lipid nanoparticles delivering VEGFC mRNA improve lymphatic function after injury.

Michalaki E, Chin R, Jeong K, Qi Z, Liebman L, Gonzalez-Vargas Y bioRxiv. 2024; .

PMID: 39131391 PMC: 11312618. DOI: 10.1101/2024.07.31.605343.


Translational frontiers: insight from lymphatics in skin regeneration.

Jiang Y, Perez-Moreno M Front Physiol. 2024; 15:1347558.

PMID: 38487264 PMC: 10937408. DOI: 10.3389/fphys.2024.1347558.


References
1.
Singer A, Clark R . Cutaneous wound healing. N Engl J Med. 1999; 341(10):738-46. DOI: 10.1056/NEJM199909023411006. View

2.
Partanen T, Alitalo K, Miettinen M . Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999; 86(11):2406-12. View

3.
Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V . VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 1996; 122(12):3829-37. DOI: 10.1242/dev.122.12.3829. View

4.
Jussila L, Valtola R, Partanen T, Salven P, Heikkila P, Matikainen M . Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998; 58(8):1599-604. View

5.
Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M . VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999; 154(5):1381-90. PMC: 1866582. DOI: 10.1016/S0002-9440(10)65392-8. View